Vitamin D depletion aggravates hypertension and target-organ damage

Andersen, Louise Bjørkholt; Przybyl, Lukasz; Haase, Nadine; von Versen-Höynck, Frauke; Qadri, Fatimunnisa; Jørgensen, Jan Stener; Sorensen, Grith Lykke; Fruekilde, Palle; Poglitsch, Marko; Szijarto, István; Gollasch, Maik; Peters, Joerg; Muller, Dominik N; Christesen, Henrik Thybo; Dechend, Ralf

Published in:
Journal of the American Heart Association

DOI:
10.1161/JAHA.114.001417

Publication date:
2015

Document version
Final published version

Citation for published version (APA):
Andersen, L. B., Przybyl, L., Haase, N., von Versen-Höynck, F., Qadri, F., Jørgensen, J. S., ... Dechend, R. (2015). Vitamin D depletion aggravates hypertension and target-organ damage. Journal of the American Heart Association, 4(2). https://doi.org/10.1161/JAHA.114.001417

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying this open access version.

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Vitamin D Depletion Aggravates Hypertension and Target-Organ Damage

Louise Bjørkholm Andersen, MD; Lukas Przybyl, MSc; Nadine Haase, PhD; Frauke von Versen-Hüynck, MD; Fatimunnisa Qadri, PhD; Jan Stener Jørgensen, PhD; Grith Lykke Sorensen, PhD; Palle Fruekilde, MSc; Marko Poglitsh, PhD; István Szijarto, PhD; Malik Gollasch, PhD; Joerg Peters, MD; Dominik N. Muller, PhD; Henrik Thybo Christesen, PhD;* Ralf Dechend, MD*

Background—We tested the controversial hypothesis that vitamin D depletion aggravates hypertension and target-organ damage by influencing renin.

Methods and Results—Four-week-old double-transgenic rats (dTGR) with excess angiotensin (Ang) II production due to overexpression of the human renin (hREN) and angiotensinogen (hAGT) genes received vitamin D-depleted (n=18) or standard chow (n=15) for 3 weeks. The depleted group had very low serum 25-hydroxyvitamin D levels (mean±SEM; 3.8±0.29 versus 40.6±1.19 nmol/L) and had higher mean systolic BP at week 5 (158±3.5 versus 134.6±3.7 mm Hg, P<0.001), week 6 (176.6±3.3 versus 162.3±3.8 mm Hg, P<0.01), and week 7 (171.6±5.1 versus 155.9±4.3 mm Hg, P<0.05). Vitamin D depletion led to increased relative heart weights and increased serum creatinine concentrations. Furthermore, the mRNAs of natriuretic peptides, that even short-term severe vitamin D deficiency may directly promote hypertension and impacts on renin-angiotensin system components that could contribute to target-organ damage. The findings add to the evidence that vitamin D deficiency could also affect human hypertension. (J Am Heart Assoc. 2015;4:e001417 doi: 10.1161/JAHA.114.001417)

Key Words: hypertension • renin • vitamin D
Vitamin D Depletion, Hypertensive Damage

Andersen et al

Methods

We purchased dTGR rats (n=33) and non-transgenic control Sprague-Dawley rats (n=12) from Harlan A/S. Our local review board (State Office of Health and Social Affairs [LAGeSo], permit number G160/09) approved the studies that complied with guidelines from the American Physiology Society. Age-matched male dTGR and non-transgenic Sprague-Dawley rats at weaning (age 4 weeks) were given free access to drinking water and either a vitamin D-decient diet with normal calcium and phosphorus, or a diet with normal vitamin D amounts (AIN93G; SSNIFF, Germany). Systolic BP was measured under light anesthesia weekly by tail-cuff. The “Tail cuff” apparatus was built by the workshop of our institute. Light anesthesia was employed to ensure correct and safe handling of the rats during the procedure. The animals were placed in metabolic cages once weekly, and 24-hour urine albumin excretion (ELISA; CellTrend) was measured. Rats were killed by guillotine at age 7 weeks, after light ether anesthesia to ensure safe and correct handling. Blood for hormone analysis was drawn as previously reported for human RAS in a rat model. Following elution and solvent evaporation, samples were reconstituted in 50 μL 50% acetonitrile/0.1% formic acid and subjected to LC-MS/MS analysis using a reversed-phase analytical column (Luna C18, Phenomenex) using a gradient ranging from 10% acetonitrile/0.1% formic acid to 70% acetonitrile/0.1% formic acid in 9 minutes. The elute was analyzed in line with a QTRAP-4000 mass spectrometer (AB Sciex) operated in the MRM mode using dwell times of 25 msec at a cone voltage of 4000 volts and a source temperature of 300°C. For each peptide and corresponding internal standards, 2 different mass transitions were measured. Ang peptide concentrations were calculated by relating endogenous peptide signals to internal standard signals provided that integrated signals achieved a signal-to-noise ratio above 10. We calculated ACE1 activity according to the established ratio; ACE-1 activity was estimated as Ang II/Ang 1 to 10 and ACE-2 activity was estimated as Ang 1 to 7/Ang 1 to 8. For vitamin D determinations, serum was stored at −20°C until analysis, which was performed as previously reported for human serum. Briefly, vitamin D2 and D3 were measured as individual components in one single analysis on a TurboFlow LC-MS/MS system (TLX2 HPLC with a Vantage TSQ MS, all from Thermo Scientific). For internal standard, d3-25-OH-vitamin D3 (Sigma-Aldrich) was used. Calibration curves were verified with NIST 972 and 2972.

Spleens and heparinized blood for analysis of regulatory T cells were collected from dTGR in the 2 groups (depletion and control) at the time of death. Tissues were minced through 70 μm sieves and washed with cold PBS containing 0.1% FCS. Flow-through and blood were subjected to osmotic lysis of red blood cells at 37°C. Next, cell suspension was filtered through 40 μm sieves, diluted and centrifuged at 300g for 10 minutes, at 4°C. Cells were then washed twice using cold PBS/ FCS buffer. Cells in single-cell suspension were stained with anti-CD4, anti-CD25, and permeabilized and stained with anti-FoxP3 (FoxP3 kit from BioLegend, San Diego, CA, CD4-FITC.
Results

After 3 weeks, the group receiving vitamin D-depleted chow (VDd-dTGR) had very low serum 25(OH)D3 levels of 8.71 ± 0.6 nmol/L, whereas the controls (ctl-dTGR) had levels of 40.6 ± 2.9 nmol/L (Figure 1A). None of the groups had detectable levels of 25(OH)D2. Systolic BP was higher in the VDd-dTGR group relative to ctl-dTGR throughout the study. Already at week 5, VDd-dTGR had higher systolic BP at 158.6 ± 3.5 versus 134.6 ± 3.7 mm Hg, P < 0.001, week 6 176.6 ± 3.3 versus 162.3 ± 3.8 mm Hg, P < 0.01, and week 7 171.6 ± 5.1 versus 155.9 ± 4.3 mm Hg, P < 0.05 (Figure 1B).

Both depleted and control dTGR displayed substantial cardiac hypertrophy. Log-transformed relative heart weight was significantly higher for VDd-dTGR (0.75 ± 0.01 versus 0.71 ± 0.01 mg/g, P < 0.01) (Figure 2A). Relative expression of markers of heart failure were significantly higher in heart tissue from the depletion group, atrial natriuretic peptide (ANP) at 0.80 ± 0.06 versus 0.60 ± 0.05 arbitrary units (AU), P < 0.05 and brain natriuretic peptide (BNP) at 0.83 ± 0.06 versus 0.57 ± 0.07 AU, P < 0.01 (Figure 2B). Albuminuria was present in both groups, but did not differ significantly at any time point (Figure 3A). The VDd-dTGR group exhibited substantially higher relative mRNA expression of neutrophil gelatinase-associated lipocalin (N-GAL) in kidney tissue than the ctl-dTGR, at 2.10 ± 0.3 versus 1.30 ± 0.15 AU, P < 0.05 (Figure 3B), and higher plasma creatinine levels at 22.43 ± 0.48 versus 18.83 ± 0.87 μmol/mL, P < 0.01 as well as a tendency towards higher plasma cystatin C levels at 2260 ± 146 versus 1929 ± 110 ng/mL, P = 0.1. Tissue analyses for inflammation and fibrosis by immunohistochemistry showed no difference between depleted and control dTGR in heart and kidney tissue (Figures 4 and 5). Vitamin D depletion in non-transgenic Sprague-Dawley rats had no effect on blood pressure, proteinuria, GFR, absolute and relative heart weight, renal N-GAL, and cardiac BNP expression, compared with control rats with normal diet (data not shown). We did not observe an effect on renal rRenin and liver rAogen expression by vitamin D depletion (data not shown).

To investigate the vitamin D-mediated molecular mechanism, we investigated whether the RAS was induced by vitamin D depletion. Analysis of mRNA showed that both human and rat renin were up-regulated in the VDd-dTGR compared to ctl-dTGR, human renin at 1.81 ± 0.33 versus 0.89 ± 0.13 AU, P < 0.05 and rat renin at 1.16 ± 0.14 versus 0.77 ± 0.08 AU, P < 0.05 (Figure 6A). Liver tissue was examined for relative mRNA expression of human and rat angiotensinogen, however there were no significant differences in expression between VDd-dTGR and ctl-dTGR (Figure 6B). PRC and PRA were increased in VDd-dTGR (Table 1). Similarly, Ang I generation was significantly higher in the circulation of VDd-dTGR compared with controls. Nine of 10 angiotensin metabolites (Table 2) were significantly up-regulated in the VDd-dTGR group, including Ang II and Ang 1 to 7.

Figure 1. Serum 25(OH)D3 concentration and systolic blood pressure. A, Vitamin D-depleted rats had a significant decrease in serum 25-hydroxyvitamin D3 after 3 weeks on vitamin D-depleted chow. Results are expressed as mean ± SEM of at least 6 animals per group. B, Systolic BP increased progressively in vehicle-treated dTGR from week 5 to week 7. Vitamin D depletion increased BP from week 5 to 7. BP indicates blood pressure; ctl-dTGR, controls double-transgenic rats; VDd, vitamin D-depleted.
Moreover, ACE-1 activity (estimated as Ang II/Ang 1 to 10) and ACE-2 activity (estimated as Ang 1 to 7/Ang 1 to 8) were not different between the 2 groups. Because vitamin D is known to induce regulatory T cells, we investigated whether or not vitamin D deficiency would affect regulatory T cells (CD4+CD25+FoxP3). No difference in the spleen or in peripheral blood was found (Figure 7).

Discussion

We found that short-term dietary depletion of vitamin D aggravated both hypertension and cardiovascular target-organ damage in dTGR rats. We attribute these effects to up-regulation of both the hREN transgene and the endogenous rRen in the VDd-dTGR group, leading to increased generation of various angiotensin peptides, after only 3 weeks of vitamin D depletion. However, neither hATG nor rAgt expression nor ACE-1 or ACE-2 activity were altered by vitamin D depletion. Moreover, vitamin D depletion did not alter the relative percentages of regulatory T cells, suggesting that regulatory T-cell deficiency was not responsible for the higher BP and target-organ damage.

Several rodent studies have been conducted to investigate the effect of vitamin D supplementation on hypertension and target-organ damage, using the Dahl salt-sensitive rats and models of renal failure and nephropathy.

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Effect of vitamin D depletion on cardiac hypertrophy, BNP, and ANP expression. Vitamin D depletion-induced cardiac hypertrophy (A) expressed as ratio of heart weight to body weight. Cardiac hypertrophy indices of VDd-dTGR were significantly higher compared with ctl-dTGR. B, With RT-PCR, we examined BNP (left) and ANP (right) mRNA expression in the heart. ANP and BNP mRNA expression were significantly higher in VDd-dTGR compared with ctl-dTGR. mRNA levels of BNP and ANP were normalized for the housekeeping gene GAPDH. Results are expressed as arbitrary units (AU) with mean±SEM of at least 7 animals per group. ANP indicates atrial natriuretic peptide; BNP, brain natriuretic peptide; ctl-dTGR, controls double-transgenic rats; RT-PCR, real-time polymerase chain reaction; VDd, vitamin D-depleted.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Effect of vitamin D depletion on renal function. A, dTGR developed progressive increased 24 hours urinary albumin excretion, which was not changed by vitamin D depletion. B, Left to right: Plasma creatinine was significantly higher in VDd-dTGR. Serum cystatin C concentration was higher in VDd-dTGR, but this was only a trend (P=0.1). The expression of NGAL mRNA kidney tissue was significantly higher in VDd-dTGR compared with ctl-dTGR. mRNA levels of NGAL were normalized for the housekeeping gene 18S. Results are expressed as arbitrary units (AU) with mean±SEM of at least 7 animals per group. ctl-dTGR indicates controls double-transgenic rats; VDd, vitamin D-depleted.
Figure 4. A and B, Masson Goldner staining for fibrosis in formalin fixed paraffin-embedded kidney sections (top: lower magnification, middle: higher magnification). C, Macrophage immunofluorescent staining (ED1) in formalin-fixed paraffin-embedded Kidney Sections and quantification of ED1-positive Cells. All measurements were performed in double transgenic rats with normal diet (VDs-dTGR) and after vitamin D depletion (VDd-dTGR). dTGR indicates double-transgenic rats; VDd, vitamin D-depleted.
Figure 5. A and B, Picro Sirius Red staining for fibrosis in formalin fixed paraffin-embedded heart Sections (top: lower magnification, middle: higher magnification). Quantification of Fibrosis in Picro Sirius Red staining (C) Immunofluorescence staining of macrophages (ED1) in formalin-fixed paraffin-embedded heart sections and quantification (% Area Measured as Area related to whole LV). All measurements were performed in double transgenic rats with normal diet (VDs-dTGR) and after vitamin D depletion (VDd-dTGR). dTGR indicates double-transgenic rats; LV, left ventricle; VDd, vitamin D-depleted.
Most of these studies found an ameliorating effect. Li et al showed that vitamin D-receptor deletion in mice leads to up-regulation of both rodent renin mRNA and protein expression in the kidney. These mice had elevated renin and Ang II concentration, as well as hypertension and target-organ damage. Furthermore, 1,25(OH)2D3 is involved in transcriptional repression of renin expression, through a cyclic AMP response element in the renin gene promoter. A mouse model of 1α-hydroxylase-gene deletion showed that the enzyme protects the cardiovascular system by suppressing the RAS. Six-week vitamin D depletion in LDL-receptor and apolipoprotein E-null mice resulted in reversible increases in systolic and diastolic BP with elevated plasma renin. The null mice develop substantial renal and cardiovascular target-organ damage compared to controls. The induction of renin is independent of calcium and parathyroid hormone and is a direct effect of altered 1,25(OH)2D3 levels. In juxtaglomerular cells 1,25(OH)2D3 directly suppressed renin gene transcription, which was dependent on the vitamin D receptor. Treatment of juxtaglomerular cells with 1,25(OH)2D3 decreased promoter activity of a transfected

Table 1. Plasma Renin Concentration and Activity (Mean±SEM)

| Parameter                        | ctl-dTGR       | VDd-dTGR      | P Value |
|----------------------------------|----------------|---------------|---------|
| PRC (sheep substrate) ng Ang I/(mL per h) | 16.45±7.3      | 26.58±12.5    | 0.05    |
| PRC (rat substrate) ng Ang I/(mL per h) | 11.47±3.4      | 23.29±9.1     | 0.01    |
| PRA ng Ang I/(mL per h)          | 35.79±35.81    | 54.22±38.8    | 0.34    |
| Ang I ng/mL                      | 4.98±1.6       | 8.58±2.5      | 0.01    |

Ang I indicates angiotensin I; ctl-dTGR, controls double-transgenic rats; PRA, plasma renin activity; PRC, plasma renin concentration; VDd, vitamin D-depleted.
The molecular mechanism of the vitamin D induced renin down-regulation is only partially understood. 1,25(OH)₂D₃ blocks the formation of the cyclic AMP response element-binding protein (CREB) and the related partner complex. Furthermore, the transcriptional regulatory complex made up of CREB1, nuclear receptor corepressor 1 (NCOR1), and the vitamin D receptor, which bind to the cyclic AMP response element-like domain in the renin enhancer, are also important in the suppression of renin.

In infants, reversible cardiomyopathy has been reported in infants with nutritional rickets, and simultaneously low vitamin D and calcium levels. Furthermore, a recent study of taketsubo-cardiomyopathy in adult women also suggested an association to low vitamin D levels. Randomized clinical trials of vitamin D supplementation for reduction of BP in humans are conflicting. A recent trial meta-analysis of the effect of oral vitamin D supplementation on BP showed a trend towards a reduction in diastolic BP and a small, but significant reduction in diastolic BP, in patients with preexisting cardiovascular risk. In a trial with hypertensive patients, the group receiving vitamin D supplementation showed a 4 mm Hg decrease in central systolic BP. In patients with baseline 25OHD <80 nmol/L, a decrease in both systolic and diastolic BP was observed. Others found a significant decrease in systolic BP with calcitriol intervention in hypertensive patients or paricalcitol intervention in diabetic patients. However, The Women’s Health Initiative trial with vitamin D and calcium intervention, failed to show an effect of vitamin D on BP or incident hypertension. Another trial of chronic renal disease patients found no effect of paricalcitol therapy on BP.

Our study supports the idea that profoundly low 25(OH)D levels may aggravate hypertension and adds mechanistic information. To our knowledge, no studies have previously focused on the effect of short-term vitamin D depletion in humans.

In earlier studies, we showed that both human and rat renin mRNA were expressed in the kidneys of dTGR. However, the 2 renin mRNAs were decreased, indicating a physiological down-regulation probably by high BP. Our current experiments show that the up-regulation of rat renin by vitamin D depletion is important and pronounced, since it overcomes the expected down-regulation by high BP. We observed an effect on BP after only 3 weeks of depletion, which points towards a very rapid effect of vitamin D depletion on hypertension. This finding is clinically interesting as it suggests that the human renin-angiotensin axis may be quite sensitive to changes in serum levels of 25(OH)D. Vitamin D-binding protein and serum albumin both bind 25(OH)D, and a measurement of the 2 binding proteins could have enabled us to calculate the amounts of bioavailable 25(OH)D in the rat circulations. However, in this study, depletion of dTGR rats resulted in very low levels of vitamin D (8±0.7 nmol/L versus 40.6±2.9 nmol/L) and it is reasonable to assume that the proportion of bioavailable vitamin D would be correspondingly very low, if not negligible. Calculation of the bioavailable fraction might be of more value in an intervention study with supplementation, where it is of interest to find the increase in bioactive vitamin D. A further limitation to our study is not using radiotelemetry for measuring blood pressure. Yet, the tail cuff method has been used by the group in research with this transgenic rodent model for many years, and is reliable and reproducible.
particularly seeing as the animals develop very high blood pressures. However, radiotelemetry could have been more accurate in this experimental setting.

Our group previously demonstrated that adoptive regulatory T-cell transfer could ameliorate angiotensin-II induced target-organ damage.\textsuperscript{48} In addition, vitamin D has been shown to regulate relative numbers and activity of regulatory T cells in experimental and clinical studies.\textsuperscript{12,49} These observations caused us to investigate regulatory T cells in the current study. However, we did not find any evidence that splenic or peripheral numbers of regulatory T cells differed between groups.

We also observed that the Ang ratios, indicating ACE-1 and ACE-2, activity were not influenced by vitamin D depletion. We determined the expression of rat and human renin and angiotensinogen in liver and kidney and measured the concentrations of Ang metabolites in the serum by mass spectroscopy. Our findings lead us to conclude that the differences induced by vitamin D depletion were based solely on the up-regulation of renin expression and activity. The induction of renin subsequently leads to a higher serum concentration of Ang metabolites, while other enzymes of the RAS were not induced by vitamin D depletion. Instead, we observed a direct effect on the \textit{hREN} transgene. Interestingly, the \textit{hREN} transgene harbors the human renin gene promoter including all its flanking regions,\textsuperscript{50} the proposed site of 1,25 \((\text{OH})_2\text{D}_3\) action.\textsuperscript{14}

**Conclusion**

Blockade of the renin-angiotensin system with ACE inhibitors, AT1 receptor blockers, or direct renin inhibitors, all increase circulating renin. Conceivably, vitamin D supplementation or substitution in severe vitamin D deficiency could blunt this
increase. This hypothesis could be tested in subsequent translational studies. Furthermore, by adding anti-hypertensive drugs not targeting the RAS system to studies with dTGR rats, the degree of non-hypertensive Ang II induced organ damage could be established.

Acknowledgments

We thank Jutta Meisel, May-Britt Köhler, Juliane Anders, Jana Czychi, and Ute Gerhard for their technical assistance. Friedrich C. Luft helped us with the manuscript.

Sources of Funding

Funding sources include University of Southern Denmark, Odense University Hospital. Dechend and Versen-Hoeynick are funded by DFG (German Research Foundation DE631/9-1 and VE 490/7-1). The funding sources had no role in study design, data interpretation, or decision to submit for publication.

Disclosures

None.

References

1. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mansan JE, Mayne ST, Ross AC, Shapse SA, Taylor CL. Iom committee members respond to endocrine society vitamin D guideline. J Clin Endocrinol Metab. 2012;97:1146–1152.
2. Bjelakovic G, Gluud LL, Nikolova D, Whitlock G, Schneeweiss S, Simonetti RG, Thakkinstian A, Tallens R, Gluud C. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014;1:CD007470.
3. Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, Lips P. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab. 2013;98:E1283–E1304.
4. Forman JP, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828–832.
5. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Willett WC, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063–1069.
6. Griffith FC, Gadebeku CA, Sowers MR. Vitamin D and subsequent systolic hypertension among women. Am J Hypertens. 2011;24:316–321.
7. Judd SE, Nanes MS, Ziegler TR, LaValle MN. Vitamin D status attenuates the age-associated increase in systolic blood pressure in white americans: results from the third national health and nutrition examination survey. Am J Clin Nutr. 2008;87:136–141.
8. Jorde R, Figschau Y, Emaus N, Hutchinson M, Grimes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension. 2010;55:792–798.
9. Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol. 2013;28:205–221.
10. Diaz L, Noyola-Martinez N, Barrera D, Hernandez G, Avila E, Halhali A, Larrea F. Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. J Reprod Immunol. 2009;81:17–24.
11. Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, Hewison M. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod. 2006;75:816–822.
12. Bock G, Prietl B, Mader JK, Holler E, Wolf M, Plitz S, Graninger WB, Obermayr-Pietsch BM, Pieber TR. The effect of vitamin D supplementation on peripheral regulatory T cells and beta cell function in healthy humans: a randomized controlled trial. Diabetes Metab Res Rev. 2011;27:942–945.
13. Yang YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens. 2012;21:72–79.
14. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem. 2007;282:29821–29830.
15. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–238.
16. Vaida A, Forman JP, Hopkins PN, Seely EW, Williams JS. 25-hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst. 2011;12:311–319.
17. Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, Yao X, Chen ZY, Vanhoutte PM. Huang Y. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J. 2012;33:2980–2990.
18. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649–654.
19. Vaida A, Forman JP, Hopkins PN, Seely EW, Williams JS. 25-hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst. 2011;12:311–319.
20. Dong J, Wong SL, Lau CW, Lee HK, Ng CF, Zhang L, Yao X, Chen ZY, Vanhoutte PM. Huang Y. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J. 2012;33:2980–2990.
21. Santos RA, Ferreira AJ, Verano-Braga T, Badner M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216.R1–R17.
22. Park JK, Fischer R, Dechend R, Shagdarsuren E, Galpekju A, Wellner M, Meiners S, Gratze P, Al-Saadi N, Felt S, Fiebeler A, Madwed JB, Schirdevan A, Haller H, Luft FC, Muller DN. P38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007;49:481–489.
23. Fischer R, Dechend R, Qadir F, Markovic M, Felt S, Herse F, Park JK, Galpekju A, Schwarz I, Zacharzewski UB, Pehr M, Sefak T, Heuser A, Schirdevan A, Luft FC, Muller DN. P38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2008;5:1540–546.
24. Hilgers KF, Peters J, Veelken R, Sommer M, Rupprecht G, Ganten D, Luft FC, Mann JF. Increased vascular angiotensin formation in female rats harboring the mouse ren-2 gene. Hypertension. 1992;19:687–691.
25. Anderssen L, Abrahamsson B, Dalgaard C, Kihl-Beck Nielsen F, Nissen M, Jorgensen J, Barnington T, Christensen H. Parity and tanned white skin as novel predictors of vitamin D status in early pregnancy: a population-based cohort study. Clin Endocrinol. 2013; doi: 10.1111/cen.12147 [Epub ahead of print].
26. Choi J, Ke Q, Bae S, Lee JY, Kim YJ, Kim UK, Arbeeyn C, Thadandi R, Kang PM. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Cardiof Fail, 2011;17:1051–1058.
27. Bae S, Yalamarti B, Ke Q, Choudhury S, Yu H, Karumanchi SA, Kroeger P, Thadandi R, Kang PM. Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiosci Res. 2011;91:632–639.
28. Bodnay N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadandi R, Kang PM. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007;104:16810–16815.
29. Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn D, Gardner DG, Liapis H, Siatropolsky E. Effect of combination of AIC, inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol. 2012;302:F141–F149.
30. He W, Kang YS, Dai C, Liu Y. Blockade of WNT/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22:90–103.
31. Sanchez-Nino MD, Bozic M, Cordova-Lanue A, Valcheva P, Garcia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivieso JM. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:F647–F657.
32. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25 \( \text{OH}(2) \text{D3} \)-dependent regulation of the renin-angiotensin system in \( \text{alp} \)-haydroxylase knockout mice. Kidney Int. 2008;74:170–179.
33. Weng S, Sprague JE, Oh J, Riek AE, Chin K, Garcia M, Bernal-Mizrachi C. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. *PLoS One*. 2013;8:e54625.

34. Kong J, Qiao G, Zhang Z, Liu SQ, Li YC. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. *Kidney Int*. 2008;74:1577–1581.

35. Glenn ST, Jones CA, Gross KW, Pan L. Control of renin [corrected] gene expression. *Pflugers Arch*. 2013;465:13–21.

36. Nakane M, Ma J, Ruan X, Kroeger PE, Wu-Wong R. Mechanistic analysis of VDR-mediated renin suppression. *Nephron Physiol*. 2007;107:p35–p44.

37. Maiya S, Sullivan I, Allgrove J, Yates R, Malone M, Brain C, Archer N, Mok Q, Daubeney P, Tulloh R, Burch M. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure. *Heart*. 2008;94:581–584.

38. Yilmaz O, Olgun H, Ciftel M, Kilic O, Kartal I, Iskenderoglu NY, Laloglu F, Ceviz N. Dilated cardiomyopathy secondary to rickets-related hypocalcaemia: eight case reports and a review of the literature. *Cardiol Young*. 2013; doi: 10.1017/S1047951113002023.

39. Dande AS, Sena SF, Wasserman HS, Warshofsky MK, Belsky JL. Prevalence and consequences of vitamin D insufficiency in women with takotsubo cardiomyopathy. *J Clin Endocrinol Metab*. 2013;98:E872–E876.

40. Larsen T, Mose FH, Bech JN, Hansen AB, Pedersen EB. Effect of cholecalciferol supplementation during winter months in patients with hypertension: a randomized, placebo-controlled trial. *Am J Hypertens*. 2012; 25:1215–1222.

41. Judd SE, Raiser SN, Kumari M, Tangpricha V. 1,25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. *J Steroid Biochem Mol Biol*. 2010;121:445–447.

42. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. *Lancet*. 2010;376:1543–1551.

43. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, Beresford SA, Connelly SA, Curb JD, Grimm RH Jr, Kotchen TA, Kuller LH, Wassertheil-Smoller S, Thomson CA, Torner JC. Effect of calcium and vitamin D supplementation on blood pressure: the women’s health initiative randomized trial. *Hypertension*. 2008;52:847–855.

44. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the primo randomized controlled trial. *JAMA* 2012;307:674–684.

45. Tamez H, Zoccali C, Packham D, Winger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. *Am Heart J*. 2012;164:902–9.e2.

46. Dehmel B, Mervaala E, Lippoldt A, Gross V, Bohlender J, Ganten D, Luft FC. Pressure-natriuresis and -diuresis in transgenic rats harboring both human renin and human angiotensinogen genes. *J Am Soc Nephrol*. 1998;9:2212–2222.

47. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankres E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. *J Bone Miner Res*. 2011;26:1609–1616.

48. Kvakan H, Kleineveld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Eiltok S, Gratzel P, Dechend R, Luft FC, Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. *Circulation*. 2009;119:2904–2912.

49. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. *Nat Immunol*. 2010;11:344–349.

50. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC, Ganten D. High human renin hypertension in transgenic rats. *Hypertension*. 1997;29:428–434.
Vitamin D Depletion Aggravates Hypertension and Target–Organ Damage
Louise Bjørkholt Andersen, Lukasz Przybyl, Nadine Haase, Frauke von Versen-Höynck, Fatimunnisa Qadri, Jan Stener Jørgensen, Grith Lykke Sorensen, Palle Fruekilde, Marko Poglitsch, István Szijarto, Maik Gollasch, Joerg Peters, Dominik N. Muller, Henrik Thybo Christesen and Ralf Dechend

J Am Heart Assoc. 2015;4:e001417; originally published January 28, 2015;
doi: 10.1161/JAHA.114.001417
The Journal of the American Heart Association is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/4/2/e001417